top of page

Media

ViAqua Therapeutics Announces $8.25M Investment Led by S2G Ventures to Scale RNA-Based Solutions in Aquaculture

September 5, 2023

prnewswire.jpg

HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ -- ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a US$8.25M round led by S2G Ventures with participation from Rabo Ventures, The Trendlines Group Ltd., Agriline Limited, Nutreco, I-Lab Angels and Circle Investments LLC.

Thai Union Corporate Venture Fund Expands Into Biotechnology; Invests in RNA-based Aquaculture Health Platform

June 10, 2021

thiraphong-chansiri-thai-union-group.jpe

Thai Union Group PCL has invested in biotechnology company ViAqua Therapeutics through its venture fund, joining other industry-leading strategic and financial partners in backing the start-up. At left: Thai Union Group PCL CEO Thiraphong Chansiri

News of this announcement also appeared on —

ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform

June 9, 2021

viaqua-investment.jpg

Financing will support the commercialization of the first product aimed at improving health in shrimp and support the development of additional products to improve aquatic animal health and nutrition.

News of this announcement also appeared in —

ViAqua Mentioned in Fireside Chat at GrowingIL and Start-Up Nation Central's Annual AgriFood-Tech Investors Summit

November 5, 2020

g-il-strt-n-anual-s02.jpg

ViAqua mentioned in fireside chat with Nutreco's Chief Strategy Officer Laurent Genet.   

GrowingIL and Star-Up Nation Central's Annual AgriFood-Tech Investors Summit

November 5, 2020

g-il-strt-n-anual-s01.jpg

ViAqua mentioned by Joost Matthijssen, Investment Director at Nutreco, at the GrowingIL and Start-Up Nation Central's Annual AgriFood-Tech Global Investors Summit. 

Nutreco investment

July 03, 2019

nuetreco2.jpg

Nutreco has invested in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry. ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics. Nutreco has taken a meaningful minority share that will conditionally grow over time.

VisVires investment

December 12, 2018

visvires.jpg

Singapore-based VisVires New Protein Invests in Israeli startup ViAqua to combat viral infections in aquaculture.

bottom of page